• Explore /
  • Poster
  • / Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

David Hsieh

University of Texas Southwestern Medical Center, Dallas, TX;

David Hsieh , Radhika Kainthla , Hao Zhu , Muhammad S. Beg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03519997

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 584)

DOI

10.1200/JCO.2023.41.4_suppl.584

Abstract #

584

Poster Bd #

E16

Abstract Disclosures

Similar Posters

First Author: Jia Fan

First Author: Timothy Jay Price

First Author: Jia Fan

First Author: Jennifer Robinson Diamond